Published in Medical Imaging Business Week, July 28th, 2005
The EU marketing application for MS-325, trade named Vasovist, was submitted in June 2004 by Schering AG, Epix' worldwide development and marketing partner. CHMP is the scientific committee of the European Medicines Agency (EMEA). The opinions of the CHMP generally serve as the basis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.